Bausch Health Companies (TSE:BHC) Stock Price Up 5.2% – Should You Buy?

Bausch Health Companies Inc. (TSE:BHC)’s stock price shot up 5.2% during mid-day trading on Friday . The company traded as high as C$10.74 and last traded at C$10.38. 604,900 shares changed hands during mid-day trading, an increase of 63% from the average session volume of 371,612 shares. The stock had previously closed at C$9.87.

Bausch Health Companies Trading Up 11.0%

The company has a debt-to-equity ratio of -1,831.94, a current ratio of 1.19 and a quick ratio of 0.58. The firm’s 50-day simple moving average is C$8.72 and its 200 day simple moving average is C$8.41. The firm has a market capitalization of C$3.00 billion, a price-to-earnings ratio of -16.86, a P/E/G ratio of 0.21 and a beta of 0.77.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, Director John Paulson purchased 1,782,030 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The shares were acquired at an average price of C$8.14 per share, with a total value of C$14,501,803.73. Insiders have bought 3,553,401 shares of company stock worth $27,087,675 over the last ninety days. Insiders own 11.28% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.